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Abstract
Background: Surfactant protein D (SP-D) plays important roles in innate host defense against
influenza A virus (IAV) infection. Common human polymorphisms of SP-D have been found in many
human populations and associated with increased risk of certain infections. We recently reported
that the Thr/Thr 11 form of SP-D is associated with low serum levels and assembles predominantly
as trimers as opposed to the more common multimeric forms of SP-D.
Methods: Preliminary experiments were done to establish the effects of different monoclonal
antibodies against SP-D on ability of SP-D to bind to or neutralize the virus. We then purified
natural human trimeric and multimeric forms of SP-D from amniotic fluid and tested ability of these
preparations to bind to IAV, to inhibit infectivity and hemagglutination activity of IAV in vitro.
Results: In initial experiments mAbs directed against different areas on the CRD of SP-D were
found to have differing effects on antiviral activity. Using an mAb that did not interfere with antiviral
activity of SP-D, we confirm that natural SP-D trimers had reduced ability to bind to IAV. In
addition, the trimers had reduced ability to neutralize IAV as compared to natural human SP-D
multimers as well as reduced hemagglutination inhibiting activity against several strains of IAV.
Natural SP-D trimers also had different interactions with human neutrophil peptide defensins
(HNPs) in viral neutralization assays as compared to multimeric SP-D.
Conclusion: These studies indicate that a common human polymorphic form of SP-D may
modulate host defense against IAV and give impetus to clinical studies correlating this genotype
with risk for IAV infection in susceptible groups. We also show that mAbs directed against different
areas on the carbohydrate recognition domain of SP-D can be useful for dissecting out different
functional properties of the protein.
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IAV infections are a major cause of morbidity and mortal-
ity, causing ~40,000 deaths per year in the United States
[1]. Recent episodes of transmission of avian IAV infec-
tion to humans underscore the ongoing potential for pan-
demic caused by IAV [2]. Innate immune mechanisms
provide important protection against IAV in the naïve
host. Among the innate immune proteins with significant
anti-IAV activity are Type I interferons, tumor necrosis fac-
tor, the collectins, and defensins [3-6]. Surfactant protein
D (SP-D) has particularly important roles in restricting
IAV replication and limiting the severity of inflammatory
responses during the first several days of infection [7-13].
SP-D has strong antiviral activity and mediates several
other important functions some of which may be impor-
tant during infection, including maintenance of surfactant
homeostasis in the lung, clearance of apoptotic cells,
enhancement or inhibition of uptake of various organ-
isms by phagocytes, and inhibition of inflammatory reac-
tions in the lung [8,14-19]. SP-D could also contribute to
adaptive immune responses through facilitating presenta-
tion of antigen by dendritic cells [20] and decreasing lym-
phocyte activation and proliferation [21]. SP-D has also
been shown to bind to a few host molecules including
scavenger receptor rich glycoprotein 340 (gp-340), CD14
[22], microfibril-associated protein 4 (MFAP4), decorin,
DNA and human neutrophil defensins (HNPs) [23-28].
Gp-340 and HNPs have significant anti-influenza activity
in their own right and have complex interactions with SP-
D in various assays of antiviral activity [28-32].
SP-D is a collagenous lectin that assembles as a trimer
with a globular carbohydrate recognition domain (CRD)
and an extended collagenous domain. These trimers can
further multimerize into assemblies of 4 or more trimers
linked at the N-terminus by disulfide bonds [33]. There
are several common polymorphic forms of SP-D some of
which appear to be of functional and clinical significance.
We have recently shown that the Thr/Thr11 form of SP-D
assembles in vivo and in recombinant preparations pre-
dominantly as trimers, lacking the usual higher mul-
timeric forms observed for other polymorphic forms of
SP-D [34]. The Thr/Thr11 variant occurs in approximately
17% of the Danish population and is also associated with
lower serum levels of SP-D. The trimeric form of SP-D had
reduced binding to mannan, several types of bacteria and
IAV, as compared to binding by the multimeric Met/
Met11 form of SP-D. Interestingly, despite reduced bind-
ing to these microbes, the trimeric form of SP-D had
equivalent binding to LPS [34] and to HNPs [28]. Binding
to LPS or HNPs was not found to be mediated by the cal-
cium-dependent lectin activity of SP-D (in contrast to
binding to bacteria or IAV).
Additional studies in other populations have found a sim-
ilar frequency of the Thr/Thr 11 variant of SP-D [35] sug-
gesting that the polymorphism has been conserved in
many populations. Furthermore, the Thr/Thr 11 variant
has been associated with increased risk of Mycobacterium
tuberculosis infection [36]. Conversely, the Met/Met11
form is associated with increased severity of respiratory
syncytial virus (RSV) infection [37]. We have speculated
that the Thr/Thr 11 form of SP-D may modify risk for
severe IAV infection. In the current paper we demonstrate
that natural SP-D in the trimeric form not only has
reduced ability to bind IAV, but has less viral neutralizing
activity, supporting the hypothesis that the Thr/Thr 11
form of SP-D may be associated with reduced innate
defense against IAV.
Methods
Virus preparation
IAV was grown in the chorioallantoic fluid of ten day old
chicken eggs and purified on a discontinuous sucrose gra-
dient as previously described [38]. The virus was dialyzed
against phosphate buffered saline (PBS) to remove
sucrose, aliquoted and stored at -80°C until needed. Phil-
ippines 82/H3N2 (Phil82) and Brazil79/H1N1 (Braz79)
strains were kindly provided by Dr. E. Margot Anders
(University of Melbourne, Melbourne, Australia). The A/
PR/8/34/H1N1 (PR-8) strain was a gift of Dr. Jon Abram-
son (Bowman Gray School of Medicine, Winston-Salem,
NC). The HA titer of each virus preparation was deter-
mined by titration of virus samples in PBS with thor-
oughly washed human type O, Rh(-) red blood cells as
described [38]. Post thawing the viral stocks contained ~5
× 108 plaque forming units/ml.
SP-D and HNP preparations
Recombinant human SP-D (RhSP-D) was produced in
stably transfected CHO-K1 cells as previously described
[9]. The recombinant preparation used contains the Thr11
sequence in the N-terminus and could be separated into
distinct fractions containing predominantly trimers,
dodecamers or high molecular weight multimers as previ-
ously described [8,9]. In general the dodecameric fraction
was used, except for experiments in which the activity of
purified recombinant trimers and multimers were com-
pared. Natural human SP-D was isolated from amniotic
fluid as previously described [34]. A pool of amniotic
fluid (n = 6) was centrifuged 4000 rpm, 4°C for 30 min
and purified by maltosyl agarose affinity chromatogra-
phy. SP-D eluted as two structural different forms and was
collected in fractions 3, 4 ("high molecular weight SP-D)
and 6, 7 ("low molecular weight SP-D"), respectively. As
previously demonstrated, the high molecular weight frac-
tion consists predominantly of dodecamers, whereas the
low molecular weight fraction consists of trimers. The SP-
D preparations were aliquoted and stored at -80°C andPage 2 of 10
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weeks) in general.
The innate defense protein preparations used in this
report were tested for degree of contamination with endo-
toxin using a quantitative endotoxin assay (Limulus Ame-
bocyte Lysate; Bio-Whittaker, Walkersville, MD). The final
concentrations of endotoxin in protein samples contain-
ing the highest concentrations of collectins were ~20–100
pg/ml (or 6–12 Endotoxin Units/ml using internal assay
standard). HNP-1 and HNP-2 were purchased from
Bachem Bioscience (King of Prussia, PA). The levels of
endotoxin in the HNP preparations were 15 and 25 pg/µg
of protein, respectively for HNP-1 and 2.
mAbs against SP-D
MAbs 246-04 and 246-07 were raised against SP-D by
inoculating mice with 10 µg/ml of human SP-D as previ-
ously described [39]. The 245-01 was raised against a
recombinant fragment of human SP-D composed of only
the neck and carbohydrate recognition domain (CRD),
recognizes human SP-D by Western blot in reduced and
unreduced form, and was shown to be effective for immu-
nolocalization of SP-D in human tissues. By ELISA 246-04
and 246-07 react with full length human SP-D as well and
neck plus CRD fragments; 245-01 reacts well with neck
plus CRD fragments of human SP-D but not with full
length human SP-D (data not shown). Using recom-
binant fragments of SP-D we have found that the 245-01
mAb reacts with the neck region of human SP-D. The 246-
04 and 246-07 mAbs only recognize SP-D in non-reduced
form and bind to distinct epitopes on the CRD. The 246-
07 mAb probably binds to the primary calcium and sac-
charide binding region of the CRD since it blocks binding
of SP-D to mannan [31]. In contrast, the 246-04 mAb
binds to a distinct region of the CRD and does not block
binding to mannan. The 246-04 mAb does, however,
block binding of SP-D to gp-340 [31].
Measurement of binding of SP-D to IAV
Binding of collectins to IAV were assessed by ELISA.
Briefly, wells were incubated overnight at 4°C with a
1:250 dilution of Phil82 stock in coating buffer. Follow-
ing washing with PBS, the plates were blocked with PBS
containing 2.5% fatty acid and endotoxin free BSA
(Sigma, fraction V, fatty acid free and low endotoxin;
A8806) for 3 hrs. These IAV-coated plates were then incu-
bated with SP-D preparations, followed by addition of the
246-04 monoclonal antibody (mAb) against SP-D as indi-
cated. Secondary HRP-labeled donkey anti-mouse anti-
bodies were then added. TMB substrate (BioRad Labs,
Hercules, CA) was then added and the reaction was
stopped using 1N sulfuric acid (H2SO4). The optical den-
sity was measured on an ELISA plate reader at 450 nm
wavelength. Each individual data point was performed in
duplicate. In some experiments SP-D was pre-incubated
with mAbs (as indicated in figure 1) prior to binding to
IAV.
Hemagglutination (HA) inhibition assay
HA inhibition was measured by serially diluting collectin
or other host defense protein preparations in round bot-
tom 96 well plates (Serocluster U-Vinyl plates; Costar,
Cambridge, MA) using PBS as a diluent. After adding 25
µl of IAV, giving a final concentration of 40 HA units per
ml or 4 HA units/well, the IAV/protein mixture was incu-
bated for 15 min. at room temperature, followed by addi-
tion of 50 µl of a type O human erythrocyte suspension.
The minimum concentration of protein required to fully
inhibit the hemagglutinating activity of the viral suspen-
sion was determined by noting the highest dilution of
protein that still inhibited hemagglutination. Inhibition
of HA activity in a given well is demonstrated by absence
of formation of an erythrocyte pellet. If no inhibition of
HA activity was observed at the highest protein concentra-
tion used then the value is expressed as > the maximal
protein concentration.
Fluorescent focus assay of IAV infectivity
MDCK monolayers were prepared in 96 well plates and
grown to confluency. These layers were then infected with
diluted IAV preparations for 30 min. at 37°C in PBS, fol-
lowed by washing of the monolayer three times in serum
free Dulbecco's Modified Eagle Medium (DMEM) con-
taining 1% penicillin and streptomycin. The monolayers
were then incubated for 7 hours at 37°C with 5% CO2 in
DMEM. The monolayers were subsequently washed three
times with PBS and fixed with 80% acetone (volume/vol-
ume) for 10 minutes at 4°C. The monolayers were then
labeled by incubating with monoclonal antibody directed
against the influenza A viral nucleoprotein (provided by
Dr. Nancy Cox, CDC, Atlanta, GA) in reagent A (PBS with
0.1% BSA, 1% heat inactivated human serum, 0.02%
NaN3) for 30 min. at 4°C. The monolayers were washed
three times in PBS and incubated with FITC-labeled goat
anti-mouse IgG. The fluorescent foci were counted
directly under fluorescent microscopy. Initially, various
dilutions of virus were used to find the dose yielding
approximately 50 fluorescent foci per high powered (40×)
field. These foci appeared to be single infected cells in gen-
eral. In most experiments IAV was pre-incubated for 30
min. at 37°C with SP-D and/or HNPs or control buffer,
followed by addition of these viral samples to the MDCK
cells.
Statistics
Statistical comparisons were made using Student's paired,
two-tailed t test or ANOVA with post hoc test (Tukey's).Page 3 of 10
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Effect of mAbs on viral neutralizing and binding activity of SP-DFigure 1
Effect of mAbs on viral neutralizing and binding activity of SP-D. Three mAbs directed against the CRD of SP-D were 
tested as indicated. In panel A, a fixed dose of recombinant SP-D multimers (100 ng/ml) was used to neutralize the Phil82 strain 
of IAV. This concentration of SP-D reduced the number of infectious foci to 4.4 ± 1.2% of control (shown at 0 on the y axis). 
Neutralization was assessed by fluorescent focus assay and expressed as % of control infectious foci in SP-D treated samples 
compared to control. Increasing concentrations of the mAbs were pre-incubated with SP-D prior to the neutralization assay. 
The 246-07 markedly inhibited neutralizing activity (* indicates p < 0.05 vs control). Although 246-04 also inhibited neutralizing 
activity modestly as indicated its effect was significantly less than 246-07. The 245-01 antibody did not inhibit neutralizing activ-
ity but slightly increased neutralization at one concentration (indicated by **). In panel B, the 246-07 and 246-04 mAbs were 
used to detect SP-D bound to Phil82 IAV by ELISA. Recombinant SP-D multimers were used at 200 ng/ml. Where indicated the 
antibodies were added after SP-D bound to IAV or added to SP-D prior to adding SP-D to IAV. The 246-07 mAb significantly 
reduced binding of SP-D when pre-incubated with SP-D prior to addition to the virus (indicated by **). Results are mean ± SEM 
of 4 experiments.
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Testing of MAbs against SP-D in viral binding and 
neutralization assays
In our prior report we showed that natural human SP-D
multimers bind more strongly to IAV using polyclonal
anti-SP-D antibodies. We wanted to confirm this finding
using mAbs. In addition, we wanted to determine if mAbs
alter functional interactions of SP-D with IAV. As shown
in figure 1, three different mAbs were tested (245-01, 246-
04 and 246-07). The 246-07 mAb inhibits binding of SP-
D to mannan [31]. The 246-04 mAb inhibits binding of
SP-D to gp-340 but does not inhibit binding to mannan
[31]. As shown in figure 1, pre-incubation of the 246-07
mAb with SP-D strongly interfered with the IAV neutraliz-
ing activity of SP-D against the Phil82 strain of IAV. The
246-04 only slightly interfered with neutralizing activity
by comparison. The 245-01 binds to the neck region of
SP-D and did not interfere and at one concentration with
neutralizing activity of SP-D. Similar results were obtained
in HA inhibition assays: 246-07 interfered with HA inhib-
iting activity of SP-D but the other mAbs did not (Table
1).
We next tested the effects of the mAbs in an ELISA assay
for binding of SP-D to IAV. In the first set of experiments
we incubated IAV with recombinant human SP-D
dodecamers and then added mAbs. Bound antibodies
were detected with HRP labeled goat anti-mouse antibod-
ies. As shown in panel B of figure 1, the 246-04 and 246-
07 mAbs recognized SP-D bound to IAV to a roughly sim-
ilar extent. We then tested the effect of pre-incubating SP-
D with the mAbs followed by addition of the mixture to
the virus-coated plates. Using this method, binding of SP-
D was unaffected by the 246-04 mAb but was markedly
reduced by the 246-07 mAb.
Natural and recombinant SP-D trimers bind less strongly to 
IAV than multimers
In initial experiments we coated natural SP-D multimers
and trimers on ELISA plates and tested for detection with
MAb 246-04. This mAb was found to detect natural
human SP-D trimers to a similar, if not greater, extent
than it detected natural SP-D multimers (data not
shown). Since the 246-04 mAb also did not alter func-
tional interactions of SP-D with IAV, we used this mAb to
detect binding of the natural and recombinant human
trimers and multimers to IAV (figure 2). These assays con-
firmed that the natural multimers bound much more
strongly to IAV (figure 2; panel A). Of interest, recom-
binant SP-D containing the Thr11 sequence forms a com-
plex mixture of trimers, dodecamers and high molecular
weight multimers in vitro which can be separated isolated
using gel filtration [9]. We compared IAV binding activity
of purified trimers and high molecular weight multimers
(figure 2; panel B) and found greater binding activity for
the multimers using these preparations also.
Natural human SP-D multimers have greater viral 
neutralizing and HA inhibiting activity than trimers
Using a fluorescent focus assay for viral neutralization, SP-
D multimers had significantly greater neutralizing activity
against the Phil82 strain of IAV compared to trimers (fig-
ure 3). Although neutralizing activity of the trimers was
reduced compared to multimers, the trimers did have sig-
nificant neutralizing activity. SP-D multimers also had sig-
nificantly greater activity in the HA inhibition assay
against three different IAV strains (Table 2). Similar results
were obtained with multiple independent preparations of
the natural SP-Ds (data not shown). Of interest the natu-
ral multimers had measurable HA activity against the PR-
8 strain of IAV. This strain is generally resistant to col-
lectins due to a lack of high mannose carbohydrates on its
envelope proteins [7,40-42]. Activity of the SP-D multim-
ers against PR-8 was significantly less than activity against
the representative recent human strains, Phil82 and
Braz79.
SP-D multimers have distinct interactions with HNP in 
viral neutralization assays
We have previously reported that SP-D binds to HNPs via
its CRD through a mechanism that is not dependent on
calcium or saccharides, but increased at low pH and low
ionic strength [28]. As in the case of gp-340, complex
functional interactions between HNPs and SP-D were
observed in antiviral assays. In some cases HNPs inhibited
antiviral activity of SP-D (and vice versa); less often addi-
tive effects were observed. Of interest, we found that nat-
ural human SP-D multimers and trimers had equivalent
binding to HNPs [28]. As shown in figure 4, HNPs 1 and
2 had strong viral neutralizing activity against the Phil82
strain of IAV. Natural SP-D multimers had additive effects
when combined with HNP1 or HNP2 in these assays. As
in figure 3, SP-D multimers had greater independent neu-
tralizing activity than trimers. SP-D trimers did not have
additive effects with the HNPs, rather they showed a trend
toward interference with the antiviral activity of HNPs.
Table 1: Effect of mAbs on ability of SP-D to inhibit viral 
hemagglutination activity
MAb added: None 245-01a 246-04 246-07
HA inhibiting conc. of SP-D
(ng/ml)b
49 ± 14 37 ± 11 55 ± 17 >420
p < 0.001
a Recombinant human SP-D multimers were pre-incubated with the 
indicated MAbs prior to adding SP-D to virus and assaying HA 
inhibition.
b The values shown are mean ± SEM (n = 4) amounts of SP-D needed 
to inhibit 40 HA units of the Phil82 strain of IAV.Page 5 of 10
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Natural SP-D multimers bind more strongly to IAV than SP-D trimersFig e 2
Natural SP-D multimers bind more strongly to IAV than SP-D trimers. Natural SP-D multimers and trimers were 
purified from amniotic fluid and tested for binding to Phil82 IAV by ELISA using the 246-04 mAb for detection of bound SP-D. 
Natural SP-D multimers showed significantly greater binding than trimers (** indicates p < 0.01; n = 3; Panel A). Binding of nat-
ural SP-D trimers was significantly above background binding to BSA at 640 ng/ml only (* indicates p < 0.01). In panel B we 
compared binding of recombinant human trimers and multimers isolated by gel filtration. Again binding of multimers was signif-
icantly greater than binding of trimers. In panel B background binding to BSA coated plates was subtracted from the results 
shown.
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There is increasing evidence that the relatively common
Thr/Thr11 polymorphism of SP-D has important implica-
tions for innate host defense against infection. This poly-
morphism is associated with reduced serum levels of SP-
D and generation of predominantly trimeric SP-D in vitro
and in vivo [34]. Furthermore the Thr/Thr11 polymor-
phism has been associated with increased risk for M. tuber-
culosis in Mexico [36]. We now confirm that natural SP-D
trimers have reduced ability to bind to IAV, and further
demonstrate that the trimers have reduced neutralizing
and HA inhibiting activity against IAV. It will be impor-
tant to confirm these results with more preparations of
natural SP-D, including samples obtained from broncho-
alveolar lavage fluid, and recombinant forms of the Thr/
Thr11 and Met/Met11 variants; however, the findings are
consistent with prior studies using other full length
trimeric and more highly multimerized forms of recom-
binant SP-D [9,33,43]. The difference in activity appears
to relate predominantly to differences in multimerization
since trimers and multimers of recombinant SP-D (both
of which were derived from a plasmid containing the
Thr11 sequence) also showed differences in viral binding
activity. Recent studies have also shown that a recom-
binant mutant form of SP-D that lacks the collagen
domain altogether but can still form multimers by
disulfide bond formation at the N-terminus retains strong
antiviral activity in vitro and in vivo [44]. This finding
strongly supports the concept that multimerization is a
major determinant of antiviral activity.
An unresolved question is why subjects with the Thr11/
Thr11 genotype tend to predominantly form trimers and
to have lower blood levels of SP-D in vivo, whereas
recombinant proteins with this genotype can form
dodecamers and multimers as well as trimers. It is possi-
ble that the Thr11/Thr11 variant, or multimers formed by
it, are less stable in vivo for reasons yet to be determined.
Our findings obtained with mAbs directed against SP-D
are of independent interest, since they show that an anti-
body directed against the region of the SP-D CRD that
mediates binding to gp-340 does not interfere with antivi-
ral activities of SP-D. Furthermore, we confirm that the
carbohydrate binding activity of SP-D (as assessed with
the 246-07 mAb that blocks SP-D binding to mannan) is
critical for antiviral activity. Further studies of epitope
mapping of the SP-D CRD coupled with studies on the
ability of mAbs to interfere with functional activities will
be of interest.
Overall our findings suggest that the Thr/Thr11 variant
may be associated with increased susceptibility to IAV
infection and that studies correlating SP-D genotype with
IAV susceptibility should be pursued. Since SP-D is one of
a number of innate factors involved in defense against
Natural SP-D multimers cause greater neutralization of IAV th n trimersFig e 3
Natural SP-D multimers cause greater neutraliza-
tion of IAV than trimers. Neutralization of IAV was 
assessed as in figure 1. Phil82 IAV was pre-incubated with SP-
D at the indicated concentrations prior to infection of 
MDCK cells. Both SP-D multimers and trimers caused neu-
tralization of IAV (* p < 0.05 compared to control); however, 
the effect of multimers was significantly greater than trimers 
(** indicates p < 0.05 compared to control or SP-D trimers). 
Neutralization by trimers and multimers was also significantly 
different when analyzed by ANOVA. Results are mean ± SEM 
of 5 experiments.
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Table 2: Comparison of HA inhibition of IAV strains by SP-D multimers and trimers
Viral Strain: Phil82 H3N2 PR-8 H1N1 Braz79 H1N1
SP-D multimers 266 ± 47a 2200 ± 423 259 ± 40
SP-D trimers ≥2062 ± 437
p < 0.01 vs multimers
>2500 ≥1750 ± 459
p < 0.01 vs multimers
a HA inhibition was measured using human Type O erythrocytes as described. The results shown are the minimal concentrations of SP-D needed to 
inhibit 40 HAU of the indicated viral strains (mean ± SEM; n = 3–5 experiments). Where ≥ is shown some of the values were above the maximum 
concentration of SP-D added (i.e., 2500 ng/ml).Page 7 of 10
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high risk populations (e.g., the elderly, infants, or subjects
with other impairments of host defense) where effects of
SP-D would be more likely to manifest themselves. The
trimers also had different interactions with HNPs. The
findings could have implications for host defense in some
circumstances (e.g., inflammatory conditions where high
concentrations of HNPs are present in the lung).
It is unclear what evolutionary pressure may have led to
retention of an apparently less active form of SP-D. Man-
nose-binding lectin (MBL) deficiency is also present in a
percentage of many populations and is associated with
increased severity of a variety of infections. However, MBL
deficiency also seems to play a deleterious pro-inflamma-
tory role in some circumstances and subjects with MBL
deficiency are protected against leishmaniasis and Myco-
bacterium tuberculosis associated meningitis [45]. One pos-
sibility, therefore, is that the Thr/Thr11 or other common
polymorphic forms of SP-D are associated with reduced
morbidity for some infections. SP-D plays an important
role in innate defense against RSV infection based on in
vitro and murine in vivo studies [46]. It is interesting there-
fore that the Met/Met11 polymorphism is associated with
more severe RSV infection [37]. We speculate that this
may reflect increased inflammatory responses to RSV
among subjects with higher levels and/or predominantly
multimeric SP-D. The only basis for this speculation is
that we found that natural SP-D trimers caused less poten-
tiation of neutrophil respiratory burst responses to IAV
than multimers [32]. It may be, therefore, that despite
reduced neutralizing activity of SP-D trimers, they are less
likely to promote inflammatory responses that could be
harmful. Findings of Gardai et al suggest that SP-D may
play either pro- or anti-inflammatory roles depending on
whether it binds to macrophages via its CRD or its colla-
gen domain [47]. These domains have distinct receptors
on macrophages which mediate anti- or pro-inflamma-
tory effects, respectively. It is unclear how oligomerization
of SP-D impacts on these interactions.
Studies in SP-D knockout mice show that the absence of
SP-D is associated with increased replication of IAV and
RSV and increased inflammatory responses and illness
[12,48]. In the case of RSV instillation of trimeric neck and
CR domain fragments of SP-D reduces severity of infec-
tion in mice [49]. In the case of IAV over-expression of a
mutant trimeric form of SP-D in the lung of SP-D -/- mice
reduces both viral titers and inflammatory responses with-
out correcting any of the baseline abnormalities of the
mice [50]. Hence, it is possible that the neutralizing activ-
ity of SP-D trimers is sufficient to contain RSV or IAV
infection. Whether trimeric SP-D holds any advantage
with regard to inflammatory responses is not clear as yet.
Hopefully epidemiological studies will clarify the role of
SP-D oligomerization with respect to various infections
like IAV. Another important clinical study will be to deter-
mine the impact of the Thr/Thr 11 polymorphisms on lev-
els of SP-D in BAL fluid, since this also could have an
impact on host defense.
Conclusion
Polymorphic variations in SP-D result in differences in
serum levels and oligomeric structure of the protein. Most
importantly, the common Thr/Thr11 polymorphism is
associated with assembly predominantly as trimers,
whereas the more common forms of SP-D are assembled
into dodecamers or higher molecular weight multimers.
Natural trimeric SP-D has reduced ability to bind to and
neutralize IAV as well as distinct interactions with HNPs
as compared to natural SPD multimers. These findings
suggest that polymorphisms of SP-D could contribute to
susceptibility of certain individuals to IAV infection. In
Viral neutralization by HNPs alone or in combination with natural SP-D multimers and trimersF g re 4
Viral neutralization by HNPs alone or in combination 
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tions alone (control; black and gray bars), HNP1 or 2 alone 
(HNP1 or HNP2; 5 µg/ml; white bars), or combination of 
HNP1 or 2 with the SP-D preparations (HNP1 or HNP2; 
black and gray bars; SP-D concentration 350 ng/ml). SP-D 
multimers caused significantly greater neutralization than 
trimers as in figure 3 (n = 5; p < 0.01). HNPs 1 and 2 also 
caused significant neutralization on their own. When SP-D 
multimers were combined with HNPs a significant increase in 
neutralization was observed (* indicates significantly different 
from control or SP-D multimers or HNPs alone by 
ANOVA).
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CRD of SP-D have differing effects on antiviral activity
and may be useful in future studies to dissect out, or inter-
fere with, various functional properties of SP-D.
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